Trials / Completed
CompletedNCT04335253
First-In-Human Study of EOS884448 in Participants with Advanced Cancers.
Phase I/IIa First-In-Human Study of EOS884448 in Participants with Advanced Cancers.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- iTeos Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
IO-002 study is a multicenter, open-label, dose-escalation Phase I/IIa clinical study to evaluate the safety and tolerability, PK, PD, and antitumor activity of EOS884448 in participants with advanced cancers.
Detailed description
Multicenter, open-label, dose-escalation Phase I/IIa clinical study to evaluate the safety and tolerability, PK, PD, and antitumor activity of EOS884448 in participants with advanced cancers. The study will consist in a dose-escalation phase to determine the MTD, the RP2D, and the safety of EOS884448 in participants with advanced cancers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EOS884448 | Multiple Ascending Dose |
Timeline
- Start date
- 2020-02-18
- Primary completion
- 2022-04-07
- Completion
- 2022-04-07
- First posted
- 2020-04-06
- Last updated
- 2024-09-19
Locations
4 sites across 1 country: Belgium
Source: ClinicalTrials.gov record NCT04335253. Inclusion in this directory is not an endorsement.